Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly (PLAN-A)

Ipsen

Status: Withdrawn

Conditions: Acromegaly

Study type: Observational

Funder types: Industry

Identifiers

NCT04003519

A-DE-52030-368

Details and patient eligibility

About

The purpose of the study is to collect data about predictive factors for the efficacy of Lanreotide Autogel in patients with acromegaly in routine clinical practice.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female aged 18 years and older with the capacity to consent
• Signed written informed consent
• Subject with hormonally active acromegaly defined by locally measured IGF-I levels 1.3 times above the age- and sex-adjusted normal range as determined at the last routine visit before baseline and after surgery
• Subject with the intention to be treated with lanreotide autogel according to the current local SmPC (Germany, Austria) prior to study enrolment

Exclusion criteria

• Participation in an interventional trial at the same time and/or within 3 months before baseline
• Subject represented by a legal guardian